XML 168 R85.htm IDEA: XBRL DOCUMENT v3.20.4
Segmentation of key figures - Top 20 (Details 9) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations $ 48,659 $ 47,445 $ 44,751
US      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 16,484 16,280 14,618
Innovative Medicines | Top 20 products [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 29,916 28,646 26,946
Innovative Medicines | Rest of portfolio [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 9,097 9,068 7,946
Innovative Medicines | Oncology [member] | Top 20 products [member] | Tasigna [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,958 1,880 1,587
Innovative Medicines | Oncology [member] | Top 20 products [member] | Sandostatin [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,439 1,726 1,561
Innovative Medicines | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,083 1,539 1,556
Innovative Medicines | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,738 1,338 1,023
Innovative Medicines | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,542 1,297 1,028
Innovative Medicines | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,188 1,585 2,046
Innovative Medicines | Oncology [member] | Top 20 products [member] | Jakavi [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,339 975 977
Innovative Medicines | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 653 1,263 1,174
Innovative Medicines | Oncology [member] | Top 20 products [member] | Votrient [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 635 755 1,002
Innovative Medicines | Pharmaceutical [member] | Top 20 products [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,933    
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   2,086 1,874
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   485 828
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 3,003 3,551 3,341
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 920    
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,251 1,173 1,039
Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 2,497 1,114 554
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,199 1,416 1,284
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,003 1,064 1,099
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 980 1,025 1,155
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   480  
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 687    
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations     464
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 3,995 3,223 2,837
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 873 671  
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations     517
Innovative Medicines | US      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 14,342 13,789 11,864
Innovative Medicines | US | Top 20 products [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 11,126 10,679 9,654
Innovative Medicines | US | Rest of portfolio [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 3,216 3,110 2,210
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tasigna [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 859 804 817
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Sandostatin [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 837 925 440
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 644 1,003 929
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 833 481 84
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 569   556
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 315 881  
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Jakavi [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   450  
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 138 334 581
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Votrient [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 259 332 19
Innovative Medicines | US | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations     806
Innovative Medicines | US | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   169 404
Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,562 2,220 1,765
Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 459    
Innovative Medicines | US | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,277   262
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   691  
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 124 86 521
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 16 13 457
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   250  
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 318    
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations     145
Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 2,516 1,736 1,674
Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 400 304  
Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations     194
Innovative Medicines | Rest of the world [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 24,671 23,925 23,028
Innovative Medicines | Rest of the world [member] | Top 20 products [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 18,790 17,967 17,292
Innovative Medicines | Rest of the world [member] | Rest of portfolio [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 5,881 5,958 5,736
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,099 1,076 770
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Sandostatin [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 602 801 1,121
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 439 536 627
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 905 857 939
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 973 1,297 472
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 873 704 2,046
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,339 525 977
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 515 929 593
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Votrient [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 376 423 983
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Top 20 products [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,933    
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   2,086 1,068
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   316 424
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,441 1,331 1,576
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 461    
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,251 1,173 1,039
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,220 1,114 292
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,199 725 1,284
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 879 978 578
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 964 1,012 698
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations   230  
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 369    
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations     319
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,479 1,487 1,163
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 473 367  
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations     323
Operating segments [member] | Innovative Medicines      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 39,013 37,714 34,892
Operating segments [member] | Innovative Medicines | Oncology [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 14,711 14,370 13,428
Operating segments [member] | Innovative Medicines | Oncology [member] | Tasigna [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,958 1,880 1,874
Operating segments [member] | Innovative Medicines | Oncology [member] | Sandostatin [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,439 1,585 1,587
Operating segments [member] | Innovative Medicines | Oncology [member] | Afinitor/Votubia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,083 1,539 1,556
Operating segments [member] | Innovative Medicines | Oncology [member] | Promacta/Revolade [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,738 1,416 1,174
Operating segments [member] | Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,542 1,338 1,155
Operating segments [member] | Innovative Medicines | Oncology [member] | Gleevec/Glivec [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,188 1,263 1,561
Operating segments [member] | Innovative Medicines | Oncology [member] | Jakavi [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,339 1,114 977
Operating segments [member] | Innovative Medicines | Oncology [member] | Exjade/Jadenu [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 653 975 1,099
Operating segments [member] | Innovative Medicines | Oncology [member] | Votrient [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 635 755 828
Operating segments [member] | Innovative Medicines | Oncology [member] | Kisqali [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 687 480 235
Operating segments [member] | Innovative Medicines | Oncology [member] | Adakveo [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 105 1  
Operating segments [member] | Innovative Medicines | Pharmaceutical [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 24,302 23,344 21,464
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 4,410 4,776 4,558
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,933 2,086 2,046
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 4,323 3,773 3,429
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 3,003 3,223 3,341
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 920 361  
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Kesimpta [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 15    
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,900 1,825 1,767
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,251 1,173 1,039
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 2,498 1,750 1,050
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 2,497 1,726 1,028
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 6,303 6,998 7,268
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,199 1,297 1,284
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 1,003 1,064 1,023
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 980 1,025 1,002
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 452 485 464
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 393 419 463
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 360 417 445
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 4,868 4,222 3,392
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations 3,995 3,551 2,837
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member]      
Disclosure of operating segments [line items]      
Net sales to third parties from continuing operations $ 873 $ 671 $ 554